Back to search
Immune Checkpoint Inhibitor-Related Myocarditis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Immune Checkpoint Inhibitor-Related Myocarditis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Immune Checkpoint Inhibitor-Related Myocarditis trials you may qualify forThe primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants h…
This study aims to investigate the clinical classification and outcome-related biomarkers of immune checkpoint inhibitor (ICI)-related myocarditis in patients w…
Patients undergoing dual treatment with Immune checkpoint inhibitors (ICI) for various cancers, e.g. melanoma, are at increased risk of developing myocarditis a…
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of c…
Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding t…
Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge. Cardiotoxicity repre…
The goal of this prospective, multicentre study is to investigate short- and long-term cardiovascular effects in cancer patients treated with immune checkpoint…